Our Medicines
Our Stories
Global Patient Week
Skip to main content
Contact Us
Careers
Login
Logged In
U.S
Close Icon
Americas
Argentina
Spanish
Brazil
Portuguese
Canada
English
/
French
Chile
Spanish
Colombia
Spanish
Mexico
Spanish
Peru
Spanish
United States
English
Asia Pacific
Australia
English
China
Simplified Chinese
India
English
Japan
Japanese
Korea
Korean
New Zealand
English
Singapore
English
Taiwan
Traditional Chinese
Thailand
English
/
Thai
Europe
Austria
German
Belgium
English
/
Dutch
/
French
Czech Republic
Czech
Denmark
Danish
Finland
Finnish
France
French
Germany
German
Greece
Greek
Hungary
Hungarian
Ireland
English
Italy
Italian
Luxembourg
English
Netherlands
English
/
Dutch
Norway
Norwegian
Poland
Polish
Portugal
Portuguese
Romania
Romanian
Spain
Spanish
Sweden
Swedish
Switzerland
German
/
French
United Kingdom
English
Middle East
Israel
Hebrew
Saudi Arabia
English
/
Arabic
Turkey
Turkish
United Arab Emirates
English
/
Arabic
Other
Other Markets
Distributor Markets
Search
Medicines
Careers
Press Releases
Medical Information
Previous Page Icon
Previous Page Icon
Our Medicines
Patients & Caregivers
Patients & Caregivers
Our medicines
Get help paying for your medicine
Patient resources
Risk Evaluation and Mitigation Strategies (REMS)
Related links
Patient resources
Immunology Patient Resources
Our position on generic drugs
Our position on drug pricing
Healthcare Providers
Healthcare Providers
Post Study Drug Access to BMS Investigational Medicinal Products and Approved Products
champions-in-care
Pre-approval access to investigational medicines
Post study drug access to BMS investigational medicinal products and approved products
Related links
U.S. medical information
Clinical trials
Pre-Approval Access
Pre-Approval Access Request System
Researchers
Researchers
In the pipeline
Areas of Focus
In the pipeline
Our R&D team
"Golden Ticket" Contests
Translational Medicine
Clinical Trials & Research
Independent Research
Investigator Inquiry Form
The Thomas One Daniel research incubator and collaboration center
Related links
Research publications
Disclosure commitment
Our research in Neuroscience
Data sharing request process
Investors
Investors
Stock information
Financial reporting
Analyst coverage
Events and presentations
Shareholder Services
Acquisition-related information for Celgene shareholders
Investor contacts
Related links
Annual Report 2022
Dividend history
Stock split history
Investment return calculator
SEC filings
Quarterly Results
Product Sales summar
Business Development
Business Development
Our Partnerships
Why Partner With Us
Areas of Interest
Business Development Leadership Team
Begin a Discussion
Global Alliances leadership team
Early Innovation at BMS
News
News
Media contacts
Temp Media library
Media library
Publications
Bristol Myers Squibb statement on ICER Ide-cel evidence report
Bristol Myers Squibb statement on ICER mavacamten evidence report
Media contacts
Press releases
Related links
Media Contacts
RSS Feeds
Subscribe to News Email Alerts
Unsubscribe to News Email Alerts
Scientific Media Resources
Disease State Infographics
Corporate Publications
Our Stories Alerts Subscription
Our Stories Alerts Unsubscribe
About Us
About Us
our science test page
Our company
Leadership
Global Inclusion & Diversity
Responsibility
Sustainability
Contact Us
Contact-us-v2
Contact Us
Related links
Global Patient Week
Survivorship Today
History Timeline
Worldwide Locations
The Bristol Myers Squibb Foundation
People & Business Resource Groups
Our Commitment to Global Inclusion & Diversity
Position on Key Issues
Disease state resources
Hypertrophic cardiomyopathy fact sheet
Total number of likes
0
Share Icon
LinkedIn
Twitter
Facebook
Email
Whatsapp Label
insta
Bristol Myers Squibb Home
/
News and media
/
Media library
/
Disease state resources
/
Hypertrophic cardiomyopathy fact sheet
March 30, 2022
Download Icon
Download hypertrophic cardiomyopathy fact sheet - U.S.
Related tags
Cardiomyopathy,
Cardiovascular,
Disease state resources,
Fact sheet
